Eli Lilly and Company (NYSE:LLY) Stake Increased by Fifth Third Bancorp

Fifth Third Bancorp increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 413,568 shares of the company's stock after buying an additional 21,352 shares during the quarter. Eli Lilly and Company accounts for approximately 1.3% of Fifth Third Bancorp's holdings, making the stock its 15th biggest position. Fifth Third Bancorp's holdings in Eli Lilly and Company were worth $321,739,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $27,000. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $29,000. Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company's stock worth $29,000 after buying an additional 32 shares during the last quarter. Finally, Legacy Financial Group LLC bought a new position in Eli Lilly and Company during the third quarter valued at approximately $35,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of LLY traded down $20.84 during trading hours on Thursday, hitting $755.91. The stock had a trading volume of 3,199,088 shares, compared to its average volume of 3,069,363. The stock has a market capitalization of $718.24 billion, a price-to-earnings ratio of 111.33, a P/E/G ratio of 1.58 and a beta of 0.37. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company's fifty day moving average is $761.75 and its two-hundred day moving average is $670.56. Eli Lilly and Company has a 52 week low of $414.31 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the company earned $1.62 EPS. Eli Lilly and Company's revenue for the quarter was up 26.0% on a year-over-year basis. On average, analysts anticipate that Eli Lilly and Company will post 13.5 EPS for the current year.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an "overweight" rating in a report on Wednesday. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an "overweight" rating in a report on Tuesday, February 6th. Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 7th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a research report on Thursday, April 11th. Finally, TheStreet raised shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.